Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.
- Further, Dr. Reddys will receive certain sales-based milestones and tiered earn-out payments.
- In March 2016, Dr. Reddys had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co. Ltd.
Erez Israeli, Chief Executive Officer, Dr. Reddys, said: Addressing unmet patient needs in oncology remains a prime focus area for us. - E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers.
- About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.